|
|
Can You Compete? Best Practices for Nonadvanced Systemic Mastocytosis
Don’t miss this Medical Jeopardy activity, designed to provide an informative, unique, and engaging educational approach to learning about nonadvanced systemic mastocytosis (SM)! Learners will watch a modified “Jeopardy” game, and each team will be led by our expert faculty contestants, with the didactic content presented as an explanation of the correct answer to each question. Topics covered will include pathophysiology, diagnosis, treatment paradigms, including the use of tyrosine kin... |
|
|
Psoriasis Prime Time: The Role of TYK Inhibition in Psoriasis
Target Audience
This activity has been designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs. It may also be of benefit to primary care clinicians, rheumatologists, and other healthcare practitioners who are interested in the treatment of psoriasis.
Program Overview
In this edition of Psoriasis Prime Time, the faculty reviews the unique mechanism of action for allosteric tyrosine kinase 2 (TYK2) inhibitors compared with Janus kinase inhibito... |
|
|
Psoriasis With Scalp Involvement in a Patient With Skin of Color
Target Audience
This activity has been designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs. It may also be of benefit to primary care clinicians, rheumatologists, and other healthcare practitioners who are interested in the treatment of psoriasis.
Program Overview
This case will discuss the treatment of psoriasis in patients with skin of color, highlighting the challenges of treating scalp psoriasis. The faculty will review the mechanism o... |
|
|
Psoriasis Prime Time: TYK Inhibition in Hard-to-Treat Psoriasis
Target Audience
This activity has been designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs. It may also be of benefit to primary care clinicians, rheumatologists, and other healthcare practitioners who are interested in the treatment of psoriasis.
Program Overview
In this edition of Psoriasis Prime Time, the faculty reviews the use of allosteric tyrosine kinase 2 (TYK2) inhibitors in the treatment of hard-to-treat psoriasis, including the ... |
|
|
HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy
In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic targ... |
|